# ProteoBridge

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteobridge

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.proteo-bridge.co.jp
- Total disclosed funding: $1.3M
- Latest round: Series A (Jun 30, 2022)
- Investors on record: 1

## About

Established in 2018 by Eriko Fukuda and based in Tokyo, Japan, Proteobridge Co., Ltd. develops high-density protein microarrays and test kits for autoantibody validation. The technology researched by the company aims to develop a more accurate and comprehensive autoantibody detection method with a small amount of blood. In June 2022, Proteo Bridge raised JPY 180 million in Series A funding from Mirai Creation Capital. As of 2022, Ryo Kumagai is the CEO of the company, which employs 12 employees.

The company provides HuPEX™, which is a protein array with proteome-wide search capabilities that is focused on simulating the binding response that takes place in a biological organism. The firm offers technologies such as utilization of human cDNA clone resources, HuPEX™, proteome-wide protein synthesis technology, and protein array fabrication technology.

The organization plans to use the June 2022 funding to accelerate the research and development of the diagnostic kits developed by the company.

## Funding rounds

- Series A, Jun 30, 2022, $1.3M — Future Creation Capital

## Investors

- Future Creation Capital (https://capitalatlas.ai/funds/future-creation-capital) — Series A